WilmerHale Advises Verve Therapeutics in $306M IPO

WilmerHale Advises Verve Therapeutics in $306M IPO

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
Critical industry insight and formidable strength across key practices.

On June 21, 2021, Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced the closing of its initial public offering of 16,141,157 shares of its common stock, which includes 2,105,368 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share. Including the option exercise, the aggregate gross proceeds to Verve Therapeutics from the offering were approximately $306.7 million, before deducting the underwriting discounts and commissions and offering expenses. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as joint book-running managers for the offering.

The WilmerHale team advising Verve Therapeutics was led by Lia Der Marderosian, Craig Hilts and Ciara Baker, and included Timothy Kulis, Erin Garrity, Chris Shin and Alex Bloom.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel